Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue
Name:
PIIS2211124720304605.pdf
Size:
3.461Mb
Format:
PDF
Description:
Final Published Version
Author
Litchfield, KevinStanislaw, Stacey
Spain, Lavinia
Gallegos, Lisa L
Rowan, Andrew
Schnidrig, Desiree
Rosenbaum, Heidi
Harle, Alexandre
Au, Lewis
Hill, Samantha M
Tippu, Zayd
Thomas, Jennifer
Thompson, Lisa
Xu, Hang
Horswell, Stuart
Barhoumi, Aoune
Jones, Carol
Leith, Katherine F
Burgess, Daniel L
Watkins, Thomas B K
Lim, Emilia
Birkbak, Nicolai J
Lamy, Philippe
Nordentoft, Iver
Dyrskjøt, Lars
Pickering, Lisa
Hazell, Stephen
Jamal-Hanjani, Mariam
Larkin, James
Swanton, Charles
Alexander, Nelson R
Turajlic, Samra
Affiliation
Univ Arizona, Dept Canc Biol, Canc CtrIssue Date
2020-05-05
Metadata
Show full item recordPublisher
CELL PRESSCitation
Litchfield, K., Stanislaw, S., Spain, L., Gallegos, L. L., Rowan, A., Schnidrig, D., ... & Turajlic, S. (2020). Representative sequencing: Unbiased sampling of solid tumor tissue. Cell Reports, 31(5), 107550.Journal
CELL REPORTSRights
Copyright © 2020 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Although thousands of solid tumors have been sequenced to date, a fundamental under-sampling bias is inherent in current methodologies. This is caused by a tissue sample input of fixed dimensions (e.g., 6 mm biopsy), which becomes grossly under-powered as tumor volume scales. Here, we demonstrate representative sequencing (Rep-Seq) as a new method to achieve unbiased tumor tissue sampling. Rep-Seq uses fixed residual tumor material, which is homogenized and subjected to next-generation sequencing. Analysis of intratumor tumor mutation burden (TMB) variability shows a high level of misclassification using current single-biopsy methods, with 20% of lung and 52% of bladder tumors having at least one biopsy with high TMB but low clonal TMB overall. Misclassification rates by contrast are reduced to 2% (lung) and 4% (bladder) when a more representative sampling methodology is used. Rep-Seq offers an improved sampling protocol for tumor profiling, with significant potential for improved clinical utility and more accurate deconvolution of clonal structure.Note
Open access journalISSN
2211-1247PubMed ID
32375028Version
Final published versionae974a485f413a2113503eed53cd6c53
10.1016/j.celrep.2020.107550
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2020 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Related articles
- Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
- Authors: Endris V, Buchhalter I, Allgäuer M, Rempel E, Lier A, Volckmar AL, Kirchner M, von Winterfeld M, Leichsenring J, Neumann O, Penzel R, Weichert W, Glimm H, Fröhling S, Winter H, Herth F, Thomas M, Schirmacher P, Budczies J, Stenzinger A
- Issue date: 2019 May 1
- Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts.
- Authors: Kazdal D, Endris V, Allgäuer M, Kriegsmann M, Leichsenring J, Volckmar AL, Harms A, Kirchner M, Kriegsmann K, Neumann O, Brandt R, Talla SB, Rempel E, Ploeger C, von Winterfeld M, Christopoulos P, Merino DM, Stewart M, Allen J, Bischoff H, Meister M, Muley T, Herth F, Penzel R, Warth A, Winter H, Fröhling S, Peters S, Swanton C, Thomas M, Schirmacher P, Budczies J, Stenzinger A
- Issue date: 2019 Nov
- Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer.
- Authors: Wu Z, Wang M, Liu Q, Liu Y, Zhu K, Chen L, Guo H, Li Y, Shi B
- Issue date: 2020
- Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay.
- Authors: Quy PN, Kanai M, Fukuyama K, Kou T, Kondo T, Yamamoto Y, Matsubara J, Hiroshima A, Mochizuki H, Sakuma T, Kamada M, Nakatsui M, Eso Y, Seno H, Masui T, Takaori K, Minamiguchi S, Matsumoto S, Muto M
- Issue date: 2019 Dec
- Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated With Immune Checkpoint Inhibitor Therapy.
- Authors: Pinato DJ, Urus H, Newsom-Davis T, Du Parcq P, Belessiotis K, Mapara L, Gupta N, Power D, Weir J, Wong CN, Ratnakumaran RP, Dominy K, Khorashad J, Bower M
- Issue date: 2020 Feb/Mar